Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VNRX-7145 + ceftibuten food effect study in healthy volunteers
NCT05527834Phase 1Completed
- Sponsor
- Basilea Pharmaceutica
- Start
- Sep 2022
- Primary completion
- Feb 2023
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of ledaborbactam etzadroxil (3 cohorts), sponsored by Basilea Pharmaceutica. Primary endpoints: Maximum Plasma Concentration at 72 hours, Area Under the Curve from Time Zero to Last Measurable Concentration at 72 hours and 1 more. Started Sep 2022; status: completed.
02
Drugs
ledaborbactam etzadroxil
Beyond the preview
Go deeper on NCT05527834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05527834.